header
Image from OpenLibrary

Comparative Study of Salvage Chemotherapy ESHAP VS GEMOX in Relapsing Lymphoma / Ahmed Abdalhafeez Mohamed ; Supervised Hamdy Mohamed Zawam , Sherif Abdelaziz Elrefaee , Wael Abdelgawad Edesa

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Ahmed Abdalhafeez Mohamed , 2016Description: 151 P. : charts , facsimiles ; 25cmOther title:
  • دراسه مقارنه بين بروتوكول جمزار واوكساليبلاتين وبروتوكول مكون من فيبسيد وبلاتينول وسيتوزاروكورتيزون لعلاج اورام الغدد الليمفاويه المرتجعه [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Oncology (Clinical) Summary: During the study period, a total of 41 patients were included.Twenty one patients in GEMOX arm and 20 patients in ESHAP arm.DLBCL represented the most common pathological type (71.4%) in GEMOX arm and (65%) in ESHAP arm, followed by Hodgkin's lymphoma (28.6%) in GEMOX arm and (25%) in ESHAP arm.With a median follow up of 9.8 months (range 2-21.7 months), complete remission was achieved in 2 patients (9.6% and 10%) in GEMOX and ESHAP respectively .Partial remission was demonstrated in 4 cases (19%) in GEMOX arm and 5 (25%) in ESHAP arm. There was no statistically significant difference in response rate between the two arms (28.6% for GEMOX vs 35% for ESHAP), P =0.793.With respect to progression free survival, there was no statistically significant difference between the two groups (8.7 months for GEMOX vs 6.6months for ESHAP), P=0.711. Age adjusted IPI, status at relapse (refractory vs relapsed) and time to relapse (more or less than 12 months) are the most important factors affecting response rate
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.23.Ph.D.2016.Ah.C (Browse shelf(Opens below)) Not for loan 01010110071865000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.23.Ph.D.2016.Ah.C (Browse shelf(Opens below)) 71865.CD Not for loan 01020110071865000

Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Oncology (Clinical)

During the study period, a total of 41 patients were included.Twenty one patients in GEMOX arm and 20 patients in ESHAP arm.DLBCL represented the most common pathological type (71.4%) in GEMOX arm and (65%) in ESHAP arm, followed by Hodgkin's lymphoma (28.6%) in GEMOX arm and (25%) in ESHAP arm.With a median follow up of 9.8 months (range 2-21.7 months), complete remission was achieved in 2 patients (9.6% and 10%) in GEMOX and ESHAP respectively .Partial remission was demonstrated in 4 cases (19%) in GEMOX arm and 5 (25%) in ESHAP arm. There was no statistically significant difference in response rate between the two arms (28.6% for GEMOX vs 35% for ESHAP), P =0.793.With respect to progression free survival, there was no statistically significant difference between the two groups (8.7 months for GEMOX vs 6.6months for ESHAP), P=0.711. Age adjusted IPI, status at relapse (refractory vs relapsed) and time to relapse (more or less than 12 months) are the most important factors affecting response rate

Issued also as CD

There are no comments on this title.

to post a comment.